Moleculin Biotech Inc (MBRX)

09:17 AM

Moleculin to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech - GlobeNewswire

09:17 AM

09:15 AM

Late-Stage Cancer Drug Developer Moleculin Showcases Pipeline at Webull Healthcare Event - Stock Titan

09:15 AM

01:00 AM

Moleculin Biotech Reports Q2 2025 Financial Results - TipRanks

01:00 AM

Aug 13, 2025

Moleculin Reports Second Quarter 2025 Financial Results and Highlights - GlobeNewswire

Aug 13, 2025

Aug 13, 2025

Moleculin Biotech: A High-Risk, High-Reward Play in Oncology Innovation Amid Capital Constraints - AInvest

Aug 13, 2025

Aug 13, 2025

Moleculin's Cancer Drug Trial Grows Globally as Critical Data Readout Approaches in 2025 - Stock Titan

Aug 13, 2025

Aug 13, 2025

How liquid is Moleculin Biotech Inc. stockJuly 2025 Final Week & Verified Chart Pattern Signals - newsyoung.net

Aug 13, 2025

Aug 09, 2025

Moleculin Biotech MBRX 2025Q2 Earnings Preview Upside Potential Driven by Strategic Developments - AInvest

Aug 09, 2025

Aug 07, 2025

Moleculin Biotech shares rise 3.66% premarket after unveiling promising preclinical data for Annamycin. - AInvest

Aug 07, 2025

Aug 06, 2025

Moleculin Biotech shares fall 5.11% intraday despite promising preclinical data for Annamycin. - AInvest

Aug 06, 2025

Aug 06, 2025

Moleculin Biotech announces preclinical data of annamycin in liver cancer - TipRanks

Aug 06, 2025

Aug 06, 2025

Moleculin Biotech Reveals Promising Preclinical Data for Annamycin - TipRanks

Aug 06, 2025

Aug 06, 2025

Moleculin Biotech Highlights Annamycin's Potential Against Liver Cancers with Promising Preclinical Data - Quiver Quantitative

Aug 06, 2025

Aug 06, 2025

Moleculin Biotech, Inc. Unveils Promising Preclinical Data of Annamycin in Liver Cancer Treatment - GlobeNewswire

Aug 06, 2025

Aug 06, 2025

Revolutionary Cancer Treatment: Moleculin's Annamycin Targets 3 Types of Liver Cancer Without Heart Risks - Stock Titan

Aug 06, 2025

Aug 06, 2025

Moleculin Biotech shares rise 5.55% intraday after unveiling promising preclinical data for Annamycin. - AInvest

Aug 06, 2025

Aug 03, 2025

What is Moleculin Biotech Inc. company’s growth strategyMaximize returns with expert trading insights - Jammu Links News

Aug 03, 2025

Aug 03, 2025

Is Moleculin Biotech Inc. a good long term investmentAchieve unparalleled market performance - Jammu Links News

Aug 03, 2025

Aug 03, 2025

How does Moleculin Biotech Inc. compare to its industry peersInvest smarter with high-probability setups - Jammu Links News

Aug 03, 2025

Aug 03, 2025

Is it the right time to buy Moleculin Biotech Inc. stockUnlock real-time trading signals for gains - Jammu Links News

Aug 03, 2025

Aug 03, 2025

What makes Moleculin Biotech Inc. stock price move sharplyBuild a diversified portfolio for steady profits - Jammu Links News

Aug 03, 2025

Aug 03, 2025

Moleculin Biotech Releases Corporate Presentation Update - AInvest

Aug 03, 2025

Aug 03, 2025

What are the latest earnings results for Moleculin Biotech Inc.Capitalize on emerging trends for profits - Jammu Links News

Aug 03, 2025

Aug 03, 2025

What catalysts could drive Moleculin Biotech Inc. stock higher in 2025Robust financial gains - Jammu Links News

Aug 03, 2025

Aug 02, 2025

How volatile is Moleculin Biotech Inc. stock compared to the marketFree Stock Market Forecast Reports - Jammu Links News

Aug 02, 2025

Aug 02, 2025

How strong is Moleculin Biotech Inc. company’s balance sheetFree Stock Market Mentorship - Jammu Links News

Aug 02, 2025

Aug 02, 2025

Moleculin receives notice of intent to grant new European patent for Annamycin - MSN

Aug 02, 2025

Aug 01, 2025

Moleculin Biotech Inc. Ranks High in Smart Money TrackerROI Driven Equity Selection With Safety Emphasized - metal.it

Aug 01, 2025

Jul 31, 2025

What Caused the Sharp Drop in Moleculin Biotech (MBRX.O)? - AInvest

Jul 31, 2025

Jul 31, 2025

Moleculin Receives Notice of Intent to Grant New European Patent for Annamycin - GlobeNewswire

Jul 31, 2025

Jul 30, 2025

Will Moleculin Biotech Inc. Stock Benefit from AI and Green Energy TrendsAccurate Buy Point for Momentum Stocks Detected - metal.it

Jul 30, 2025

Jul 30, 2025

Moleculin receives European patent notice for cancer drug Annamycin By Investing.com - Investing.com Nigeria

Jul 30, 2025

Jul 30, 2025

Moleculin receives European patent notice for cancer drug Annamycin - Investing.com

Jul 30, 2025

Jul 30, 2025

Moleculin Biotech Secures European Patent for Annamycin - TipRanks

Jul 30, 2025

Jul 30, 2025

Moleculin Biotech, Inc. Receives Notice of Intent to Grant European Patent for Annamycin, Strengthening Market Position in Oncology - Quiver Quantitative

Jul 30, 2025

Jul 30, 2025

Breakthrough Cancer Drug Patent: Moleculin's Non-Cardiotoxic Treatment Gains EU Protection Until 2040 - Stock Titan

Jul 30, 2025

Jul 30, 2025

Why Did Moleculin Biotech Inc. (MBRX) Soar 10.08%? - AInvest

Jul 30, 2025

Jul 30, 2025

Moleculin Biotech shares fall 2.95% after-hours despite receiving notice of intent to grant new European patent for Annamycin. - AInvest

Jul 30, 2025

Jul 29, 2025

Statistical indicators supporting Moleculin Biotech Inc.’s strengthIntraday Trend Analysis for Fast Gains Released - metal.it

Jul 29, 2025

Jul 29, 2025

Why Did Moleculin Biotech Inc. (MBRX) Soar 11.82%? - AInvest

Jul 29, 2025

Jul 28, 2025

Why Moleculin Biotech Inc. stock attracts strong analyst attentionValue Investing Picks With Stability Outlined - metal.it

Jul 28, 2025

Jul 28, 2025

What are analysts’ price targets for Moleculin Biotech Inc. in the next 12 monthsConsistently exceptional gains - Jammu Links News

Jul 28, 2025

Jul 28, 2025

When is Moleculin Biotech Inc. stock expected to show significant growthAchieve breakthrough gains with smart trades - Jammu Links News

Jul 28, 2025